Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Read More…
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Phone+1-609-4952200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees19
Next Earnings Date9/12/2019 (Estimated)
OptionableNot Optionable
Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions
What is Palatin Technologies' stock symbol?
Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."
How were Palatin Technologies' earnings last quarter?
Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings data on Thursday, September, 13th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.00 by $0.06. The biopharmaceutical company had revenue of $20.62 million for the quarter, compared to analyst estimates of $6.03 million. During the same quarter in the prior year, the business earned ($0.02) earnings per share. View Palatin Technologies' Earnings History.
When is Palatin Technologies' next earnings date?
What price target have analysts set for PTN?
2 equities research analysts have issued 1-year target prices for Palatin Technologies' shares. Their predictions range from $3.00 to $8.00. On average, they anticipate Palatin Technologies' share price to reach $5.50 in the next year. This suggests a possible upside of 525.0% from the stock's current price. View Analyst Price Targets for Palatin Technologies.
What is the consensus analysts' recommendation for Palatin Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.
What are Wall Street analysts saying about Palatin Technologies stock?
Here are some recent quotes from research analysts about Palatin Technologies stock:
- 1. According to Zacks Investment Research, "Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. " (7/3/2019)
- 2. HC Wainwright analysts commented, "Our thesis on shares remains unchanged; major boxes checked and valuation disconnect exists, in our belief. Significant boxes have already been checked off, which we believe provide a derisked opportunity for investors." (1/11/2019)
Has Palatin Technologies been receiving favorable news coverage?
News articles about PTN stock have trended positive recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Palatin Technologies earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Palatin Technologies.
Who are some of Palatin Technologies' key competitors?
Some companies that are related to Palatin Technologies include Integral Diagnostics (IDX), Volpara Health Tech (VHT), Akumin (AKU), Senseonics (SENS), Senseonics (SENS), Renalytix Ai (RENX), Profound Medical (PRN), MaxCyte (MXCT), Yourgene Health (YGEN), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), BARD1 Life Sciences (BD1), Sernova (SVA) and GeneNews (GEN).
What other stocks do shareholders of Palatin Technologies own?
Who are Palatin Technologies' key executives?
Palatin Technologies' management team includes the folowing people:
- Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)
- Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)
- Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)
- Burns McClellan, VP of Investor Relations
Who are Palatin Technologies' major shareholders?
Palatin Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.62%), Vanguard Group Inc. (4.32%), Acadian Asset Management LLC (1.29%), Northern Trust Corp (1.05%), Strs Ohio (0.24%) and Wells Fargo & Company MN (0.18%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies.
Which major investors are selling Palatin Technologies stock?
Which major investors are buying Palatin Technologies stock?
PTN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., A.R.T. Advisors LLC, Acadian Asset Management LLC, Susquehanna International Group LLP, Castle Rock Wealth Management LLC, Mckinley Capital Management LLC Delaware and Citadel Advisors LLC. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies.
How do I buy shares of Palatin Technologies?
Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Palatin Technologies' stock price today?
One share of PTN stock can currently be purchased for approximately $0.88.
How big of a company is Palatin Technologies?
What is Palatin Technologies' official website?
How can I contact Palatin Technologies?
Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.
MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
